Expertise in
3
conditions

Robin E. Gasiorowski

Hospital Road, 
Concord, NSW, AU 
Expertise in
3
conditions
Hospital Road, 
Concord, NSW, AU 

Overview

Robin Gasiorowski practices practicing medicine in Concord, Australia.

Gasiorowski is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Classical Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 1 clinical trial.

Locations

Hospital Road, Concord, NSW 2139, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3

28 Total Publications

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.
Journal: Blood
Published: April 30, 2026

Frequently Asked Questions about Robin E. Gasiorowski

Is Robin E. Gasiorowski a top-rated expert for Classical Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Robin E. Gasiorowski is classified as an Distinguished expert for Classical Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Robin E. Gasiorowski participate in research or clinical trials?

Yes. Robin E. Gasiorowski has published 28 articles and abstracts on conditions like Classical Hodgkin Lymphoma. You can view a list of Robin E. Gasiorowski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gasiorowski's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile